Metadherin (MTDH), which was overexpressed and predicted a poor prognosis in cancer [90–92], conferred a therapy-resistant mesenchymal-high state in breast cancer cells, but also increased sensitivity to ferroptosis by downregulating GPX4 and SLC3A2. Here, GPX4 is linked to breast carcinoma.